Pegfilgrastim

Evidence Level: L5

Predicted Indications: 2

Pegfilgrastim

Pharmacist Assessment Report

Pegfilgrastim: From Neutropenia Support (Original Indication Not Listed) to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Pegfilgrastim is a long-acting, PEGylated form of granulocyte colony-stimulating factor (G-CSF), and eight products are currently licensed in Canada. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy (and the broader category of diabetic retinopathy). However, no clinical trials and no publications currently support this direction, so the prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report (the Canadian license records contain no indication text)
Predicted New Indication	Severe nonproliferative diabetic retinopathy
TxGNN Prediction Score	0.9989
Evidence Level	L5 (model prediction only)
Canada Market Status	Marketed (marketed DINs: 8 of 8)
Number of DINs	8 (marketed: 8)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on general knowledge, pegfilgrastim is a PEGylated G-CSF that stimulates the production of neutrophils, and it belongs to the class of hematopoietic growth factors. Its use in reducing neutropenia is established, but the data compiled for this report do not list an original indication.

A speculative link to diabetic retinopathy is that G-CSF may mobilize bone marrow-derived endothelial progenitor cells, which could in theory contribute to repair of damaged retinal blood vessels. The effect could also go the other way: increased neutrophil and progenitor-cell activity might promote inflammation and abnormal new vessel growth, which are harmful in the diabetic retina. The direction of effect is therefore uncertain, and nothing in the available data resolves it.

The two predicted indications are not independent. Diabetic retinopathy (score 0.9973) is the broader parent category of severe nonproliferative diabetic retinopathy (score 0.9989), and both come from the same model-derived association. The safety of systemic G-CSF for the retina in people with diabetes has not been established in the data reviewed here.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02529343	LAPELGA	Not specified	Not specified
02249790	NEULASTA	Not specified	Not specified
02484153	FULPHILA	Not specified	Not specified
02497395	ZIEXTENZO	Not specified	Not specified
02474565	LAPELGA	Not specified	Not specified

Three more valid single-ingredient licenses are on record: NYVEPRIA (02506238), NIOPEG (02546973) and PEXEGRA (02553945). There are no cancelled licenses.

Safety Considerations

Drug Interactions: The interaction query returned 100 records. All of the entries reviewed are rated Moderate (source: DDInter). Examples include:
- Chemotherapy and antineoplastic agents: paclitaxel, mercaptopurine, trimetrexate, azacitidine, arsenic trioxide, altretamine, abemaciclib
- Biologics and immunotherapies: aldesleukin, alemtuzumab, belantamab mafodotin, asparaginase
- Radiopharmaceuticals and radioimmunotherapy: iobenguane (I-131), fludeoxyglucose (18F), ibritumomab tiuxetan, tositumomab
- Others: levamisole, acalabrutinib, avapritinib, pegvaliase

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a high model score (L5). There are no clinical trials or publications, and the mechanism is speculative and could plausibly worsen retinal disease through inflammation or abnormal vessel growth. The package insert safety data and the mechanism of action are also missing, so the safety screening step cannot proceed.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data from DrugBank
Original approved indication text for the Canadian licenses
A literature and trial search on G-CSF, endothelial progenitor cells and diabetic retinopathy, including retinal safety in diabetic patients
Preclinical or mechanistic studies to establish whether the effect on the diabetic retina would be protective or harmful
Assessment of route compatibility (the current formulations are systemic, whereas retinal disease may call for other delivery routes)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.